The Motley Fool

Cellular Goods shares: 5 things I’d consider before buying

Cellular Goods (LSE: CBX) shares have been very popular so far. The company listed on the UK stock market last week, joining other early-stage cannabis firms including Kanabo and MGC Pharmaceuticals that have come to market recently.

But after a successful Initial Public Offering (IPO), Cellular Goods shares have been falling. For now, I’m watching the stock and I reckon the hype around this company may be subsiding.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Here are five things I’d consider before buying Cellular Goods shares myself.

#1 – The cannabis market

The cannabis market is a fast-growing one. I should highlight that cannabinoids make up a group of compounds produced by the cannabis plant. In fact cannabidiol, or CBD, is a well-known cannabinoid that many people are familiar with.

I think the reason CBD has been gaining popularity is that it can be used to treat a wide range of conditions. According to the company’s website, it can calm the mind, aid sleep and improve mood. These are just a few benefits so I’m not surprised why CBD is gaining traction rapidly.

#2 – Synthetic CBD

I think what sets Cellular Goods apart from its competitors is that it’s focused on creating synthetic CBD products. In simple terms, it’s CBD that’s created in the lab rather than derived from the plant.

So what are the benefits of synthetic CBD? Well, each batch is identical and traceable. It’s free from pesticides and impurities. In a nutshell, synthetic CBD is claimed to be a cleaner and greener way to manufacture the substance.

I’m glad to see that Cellular Goods has jumped on the issue of sustainability from the start. This means that institutional investors could include the stock in their ESG (Environmental, Social and Corporate Governance) sustainable investing portfolios.

#3 – The products

Cellular Goods is focusing on two product lines. The first being high-end skincare and the second is athletic recovery products.

It’s launching with three synthetic CBD products: a face mask, a daily skin serum and a topical sports recovery gel. The products will be sold on its website and through physical retail partnerships.

But do note that the company hasn’t actually sold any products yet! In fact, it expects to launch these in September. Cellular Goods could be successful, but for now it’s too speculative and risky for me. Its products haven’t been proven to sell to consumers. Therefore, it’s incurring costs and is loss-making.

#4 – High profile people

Also key, I feel, is that Peter Wall, the CEO of Argo Blockchain sits on the board as Non-Executive Chairman. It seems to me that he’s a bold advocator of early stage technologies and markets. Argo Blockchain shares have been in the limelight due to the recent rally in cryptocurrencies.

I can’t cover Cellular Goods without mentioning that sports star David Beckham owns a 5% stake. I guess it helps an IPO when there’s a high-profile investor involved.

#5 – Competitive market

CBD is increasingly popular right now, especially in the beauty industry. But this is a saturated market. High demand, along with Beckham’s high profile could work for Cellular Goods. Especially if he’s involved in the marketing campaigns. But I reckon, the company’s success will boil down to the quality of its products.

For now, I think Cellular Goods shares are a risky investment, but I’ll continue to monitor the stock.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.